Prithviraj Bose, MBBS, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the impact of SF3B1 mutation in myelofibrosis (MF) and other myeloid malignancies. Dr Bose first comments on the impact of this mutation on patients with myelodysplastic syndromes (MDS), and then explains how this mutation impacts patients with MF. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.